Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. TME Pharma N.V.
  6. Financials
    ALTME   NL0015000YE1

TME PHARMA N.V.

(ALTME)
  Report
Real-time Euronext Paris  -  11:21:10 2023-01-27 am EST
1.150 EUR   -3.97%
01/23Tme Pharma Provides Clinical Update on the Gloria Expansion Arm Testing Nox-A12 in Combination with Radiotherapy and Bevacizumab in Patients with Glioblastoma
CI
01/20Tme Pharma N : Half-yearly report on the liquidity contract with Invest Securities
PU
2022Tme Pharma N : announces convocation of an extraordinary general meeting of shareholders
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsFunds 
Valuation
Fiscal Period: December 2016 2017 2018 2019 2020 2021
Capitalization1 44,113,910,37,5924,417,4
Enterprise Value (EV)1 44,815,96,066,3314,210,4
P/E ratio -3,28x-2,50x-0,38x-7,28x-1,75x-1,07x
Yield ------
Capitalization / Revenue 94,3x59,6x-49,3x696x528x
EV / Revenue 95,8x68,0x-41,1x405x316x
EV / EBITDA -5,43x-3,37x-1,32x-1,57x-2,44x-0,78x
Enterprise Value (EV) / FCF -5,95x-4,66x2,59x-1,06x-3,46x-1,41x
FCF Yield -16,8%-21,4%38,7%-94,7%-28,9%-71,1%
Price to Book -17,8x-3,63x-3,95x-4,12x3,43x3,86x
Nbr of stocks (in thousands) 20,121,9101130434745
Reference price (EUR) 2 19963510258,256,223,4
Announcement Date 04/30/201704/30/201804/12/201904/22/202004/28/202104/22/2022
1 EUR in Million
Income Statement Evolution (Annual data)
Fiscal Period: December 2016 2017 2018 2019 2020 2021
Net sales1 0,470,23-0,150,040,03
EBITDA1 -8,26-4,72-4,59-4,04-5,81-13,4
Operating profit (EBIT)1 -8,42-4,75-4,62-4,06-5,82-13,5
Operating Margin -1 800%-2 030%--2 639%-16 640%-40 791%
Pre-Tax Profit (EBT)1 -10,7-5,39-10,7-0,86-10,4-14,5
Net income1 -10,7-5,39-10,7-0,86-10,4-14,5
Net margin -2 296%-2 301%--559%-29 729%-43 794%
EPS2 -671-254-270-8,00-32,2-21,9
Free Cash Flow1 -7,54-3,412,34-6,00-4,09-7,41
FCF margin -1 611%-1 459%--3 894%-11 688%-22 448%
FCF Conversion 91,3%72,3%-51,0%148%70,4%55,1%
Dividend per Share ------
Announcement Date 04/30/201704/30/201804/12/201904/22/202004/28/202104/22/2022
1 EUR in Million
2 EUR
Balance Sheet Analysis
Fiscal Period: December 2016 2017 2018 2019 2020 2021
Net Debt1 0,731,98----
Net Cash position1 --4,201,2610,27,02
Leverage (Debt / EBITDA) -0,09x-0,42x0,92x0,31x1,76x0,52x
Free Cash Flow1 -7,54-3,412,34-6,00-4,09-7,41
ROE (Net Profit / Equities) 226%168%329%38,6%-356%-237%
Shareholders' equity1 -4,75-3,20-3,26-2,232,926,10
ROA (Net Profit / Asset) -118%-156%-106%-81,3%-58,8%-82,4%
Assets1 9,093,4410,11,0617,717,5
Book Value Per Share2 -124-175-25,8-14,116,46,06
Cash Flow per Share2 11027,842,710,621,912,7
Capex1 0,020,000,010,020,040,01
Capex / Sales 4,49%0,85%-10,4%111%42,4%
Announcement Date 04/30/201704/30/201804/12/201904/22/202004/28/202104/22/2022
1 EUR in Million
2 EUR
Key data
Capitalization (EUR) 1 563 865
Capitalization (USD) 1 697 639
Net sales (EUR) 33 000
Net sales (USD) 35 823
Number of employees 13
Sales / Employee (EUR) 2 538
Sales / Employee (USD) 2 756
Free-Float 12,3%
Free-Float capitalization (EUR) 192 550
Free-Float capitalization (USD) 209 021
Avg. Exchange 20 sessions (EUR) 60 973
Avg. Exchange 20 sessions (USD) 66 189
Average Daily Capital Traded 3,90%
EPS & Dividend